Chemed (CHE) vs. Davita (NYSE:DVA) Head-To-Head Review
Davita (NYSE: DVA) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
This is a summary of current recommendations for Davita and Chemed, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chemed pays an annual dividend of $1.12 per share and has a dividend yield of 0.4%. Davita does not pay a dividend. Chemed pays out 24.9% of its earnings in the form of a dividend. Chemed has raised its dividend for 9 consecutive years.
Volatility and Risk
Davita has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Chemed has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Valuation & Earnings
This table compares Davita and Chemed’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Davita||$14.75 billion||0.98||$879.87 million||$2.61||30.30|
|Chemed||$1.58 billion||2.77||$108.74 million||$4.50||60.70|
Davita has higher revenue and earnings than Chemed. Davita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
This table compares Davita and Chemed’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
87.6% of Davita shares are held by institutional investors. Comparatively, 97.6% of Chemed shares are held by institutional investors. 2.0% of Davita shares are held by insiders. Comparatively, 4.9% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Chemed beats Davita on 11 of the 18 factors compared between the two stocks.
Davita Company Profile
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS is the provider of hospice services in an industry dominated primarily by small, non-profit, community-based hospices. VITAS provides hospice care to Medicare beneficiaries participating in these managed care programs. A portion of its VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.